Nusse Roeland 4
4 · BIO-TECHNE Corp · Filed Aug 27, 2025
Insider Transaction Report
Form 4
BIO-TECHNE CorpTECH
Nusse Roeland
Director
Transactions
- Exercise/Conversion
Common Stock
2025-08-25$21.84/sh+17,040$372,154→ 61,599 total - Sale
Common Stock
2025-08-25$56.36/sh−17,040$960,388→ 44,559 total - Exercise/Conversion
Stock Options (Right to Buy)
2025-08-25−17,040→ 0 totalExercise: $21.84From: 2016-10-29Exp: 2025-10-28→ Common Stock (17,040 underlying)
Holdings
- 15,940
Stock Options (Right to Buy)
Exercise: $25.30From: 2017-10-26Exp: 2026-10-27→ Common Stock (15,940 underlying) - 12,500
Stock Options (Right to Buy)
Exercise: $31.26From: 2018-10-25Exp: 2027-10-26→ Common Stock (12,500 underlying) - 7,592
Stock Options (Right to Buy)
Exercise: $44.96From: 2019-10-24Exp: 2028-10-25→ Common Stock (7,592 underlying) - 3,511
Stock Options (Right to Buy)
Exercise: $68.37Exp: 2034-10-24→ Common Stock (3,511 underlying) - 8,044
Stock Options (Right to Buy)
Exercise: $50.41From: 2020-10-24Exp: 2029-10-24→ Common Stock (8,044 underlying) - 3,937
Stock Options (Right to Buy)
Exercise: $61.51From: 2024-10-24Exp: 2033-10-26→ Common Stock (3,937 underlying) - 6,028
Stock Options (Right to Buy)
Exercise: $63.92From: 2021-10-28Exp: 2030-10-29→ Common Stock (6,028 underlying) - 2,532
Stock Options (Right to Buy)
Exercise: $128.81From: 2022-10-27Exp: 2031-10-28→ Common Stock (2,532 underlying) - 3,460
Stock Options (Right to Buy)
Exercise: $73.94From: 2023-10-26Exp: 2032-10-27→ Common Stock (3,460 underlying)
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.21 to $56.33 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders.